

Edgar Filing: TRIANGLE PHARMACEUTICALS INC - Form S-8

TRIANGLE PHARMACEUTICALS INC

Form S-8

September 20, 2002

AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON SEPTEMBER 20, 2002
REGISTRATION NO. 333-_____

SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM S-8
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933

TRIANGLE PHARMACEUTICALS, INC.
(Exact name of Registrant as Specified in Its Charter)

DELAWARE
(State or Other Jurisdiction of
Incorporation or Organization)

56-1930728
(I.R.S. Employer
Identification No.)

4 UNIVERSITY PLACE
4611 UNIVERSITY DRIVE
DURHAM, NORTH CAROLINA, 27707
(919) 493-5980
(Address, Including Zip Code, And Telephone Number, Including Area Code,
Of Registrant's Principal Executive Offices)

TRIANGLE PHARMACEUTICALS, INC.
1996 STOCK INCENTIVE PLAN
(Full Title of the Plans)

DANIEL G. WELCH
CHAIRMAN AND CHIEF EXECUTIVE OFFICER
TRIANGLE PHARMACEUTICALS, INC.
4 UNIVERSITY PLACE
4611 UNIVERSITY DRIVE
DURHAM, NORTH CAROLINA 27707
(919) 493-5980
(Name, Address, Including Zip Code, and Telephone Number, Including Area
Code, of Agent For Service)

CALCULATION OF REGISTRATION FEE

TITLE OF SECURITIES TO BE REGISTERED	AMOUNT TO BE REGISTERED (1)	PROPOSED MAXIMUM OFFERING PRICE PER SHARE (2)	PROPOSED MAXIMUM AGGREGATE OFFERING PRICE (2)
-----	-----	-----	-----
Common Stock, \$0.001 par value per share	3,000,000 shares	\$3.52	\$10,560,000

Edgar Filing: TRIANGLE PHARMACEUTICALS INC - Form S-8

(1) This Registration Statement shall also cover any additional shares of Common Stock which become issuable under the Triangle Pharmaceuticals, Inc. 1996 Stock Incentive Plan by reason of any stock dividend, stock split, recapitalization or other similar transaction effected without Registrant's receipt of consideration which results in an increase in the number of the outstanding shares of Registrant's Common Stock.

(2) Calculated solely for purposes of this offering under Rule 457(h) of the Securities Act of 1933, as amended, on the basis of the average of the high and low selling prices per share of the Registrant's Common Stock on September 19, 2002, as reported by the Nasdaq National Market.

PART II

INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

ITEM 3. INCORPORATION OF DOCUMENTS BY REFERENCE

This Registration Statement on Form S-8 (the "Registration Statement") relates to the registration of an additional 3,000,000 shares (the "Shares") of Common Stock, \$.001 par value, of the Registrant. The Shares are securities of the same class and relating to the same employee benefit plan, the Triangle Pharmaceuticals, Inc. 1996 Stock Incentive Plan, as those shares registered in the Registrant's Registration Statements on Form S-8, previously filed with the Securities and Exchange Commission on June 5, 1998 (Registration No. 333-56189), March 22, 1999 (Registration No. 333-74805), January 14, 2000 (Registration No. 333-94725), January 31, 2001 (Registration No. 333-54696), January 14, 2002 (Registration No. 333-76680) and May 24, 2002 (Registration No. 333-89084). The earlier Registration Statements on Form S-8 are hereby incorporated by reference.

The financial statements contained in the Registrant's Annual Report on Form 10-K for the year ended December 31, 2001 are incorporated by reference in this Registration Statement and have been so incorporated in reliance on the report of PricewaterhouseCoopers LLP, independent accountants, given on the authority of said firm as experts in auditing and accounting.

The following additional documents are incorporated by reference in this registration statement:

1. Our Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2002 filed on May 10, 2002;
2. Our Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2002 filed on August 13, 2002;
3. Our Annual Report on Form 10-K for the fiscal year ended December 31, 2001 filed on March 25, 2002, including information in our Definitive Proxy Statement in connection with our 2002 Annual Meeting of Stockholders;
4. Our Current Report on Form 8-K filed May 2, 2002, July 31, 2002, August 6, 2002, August 13, 2002, August 28, 2002 and September 19, 2002; and
5. The description of our common stock contained in our Registration

Edgar Filing: TRIANGLE PHARMACEUTICALS INC - Form S-8

Statements on Form 8-A filed October 18, 1996, February 10, 1999, June 18, 1999, August 24, 2001 and July 31, 2002.

All documents filed by the Company pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Securities and Exchange Act of 1934, as amended (the "Exchange Act") on or after the date of this Registration Statement and prior to the filing of a post-effective amendment which

II-1

indicates that all securities offered have been sold or which deregisters all securities then remaining unsold shall be deemed to be incorporated by reference in this Registration Statement and to be part hereof from the date of filing of such documents.

ITEM 8. EXHIBITS

NUMBER -----	EXHIBIT -----
5	Opinion and consent of Smith, Anderson, Blount, Dorsett, Mitchell & Jernigan, L.L.P.
23.1	Consent of PricewaterhouseCoopers LLP, Independent Accountants.
23.2	Consent of Smith, Anderson, Blount, Dorsett, Mitchell & Jernigan, L.L.P. is contained in Exhibit 5.
24	Power of Attorney. Reference is made to pages II-3 and II-4 of this Registration Statement.

II-2

SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8, and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Durham, State of North Carolina on this 20th day of September, 2002.

TRIANGLE PHARMACEUTICALS, INC.

By: /s/ Daniel G. Welch

Daniel G. Welch
Chairman and Chief Executive
Officer

POWER OF ATTORNEY

KNOW ALL PERSONS BY THESE PRESENTS:

That the undersigned officers and directors of Triangle Pharmaceuticals,

Edgar Filing: TRIANGLE PHARMACEUTICALS INC - Form S-8

Inc., a Delaware corporation, do hereby constitute and appoint Daniel G. Welch and R. Andrew Finkle and each one of them, the lawful attorneys-in-fact and agents with full power and authority to do any and all acts and things and to execute any and all instruments which said attorneys and agents, and any one of them, determine may be necessary or advisable or required to enable said corporation to comply with the Securities Act of 1933, as amended, and any rules or regulations or requirements of the Securities and Exchange Commission in connection with this Registration Statement. Without limiting the generality of the foregoing power and authority, the powers granted include the power and authority to sign the names of the undersigned officers and directors in the capacities indicated below to this Registration Statement, to any and all amendments, both pre-effective and post-effective, and supplements to this Registration Statement, and to any and all instruments or documents filed as part of or in conjunction with this Registration Statement or amendments or supplements thereof, and each of the undersigned hereby ratifies and confirms all that said attorneys and agents, or any one of them, shall do or cause to be done by virtue hereof. This Power of Attorney may be signed in several counterparts.

IN WITNESS WHEREOF, each of the undersigned has executed this Power of Attorney as of the date indicated.

II-3

Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed below by the following persons in the capacities and on the dates indicated.

SIGNATURE -----	TITLE -----	
/s/ Daniel G. Welch ----- Daniel G. Welch	Chairman of the Board and Chief Executive Officer (Principal Executive Officer)	September 20, 2002
/s/ Chris A. Rallis ----- Chris A. Rallis	Director, President and Chief Operating Officer	September 20, 2002
/s/ Robert F. Amundsen, Jr. ----- Robert F. Amundsen, Jr.	Executive Vice President and Chief Financial Officer (Principal Financial and Accounting Officer)	September 20, 2002
/s/ Anthony B. Evnin ----- Anthony B. Evnin	Director	September 20, 2002
/s/ Standish M. Fleming ----- Standish M. Fleming	Director	September 20, 2002
/s/ Dennis B. Gillings ----- Dennis B. Gillings	Director	September 20, 2002
/s/ Henry G. Grabowski	Director	September

Edgar Filing: TRIANGLE PHARMACEUTICALS INC - Form S-8

----- Henry G. Grabowski		20, 2002
/s/ Stewart J. Hen ----- Stewart J. Hen	Director	September 20, 2002
/s/ Jonathan S. Leff ----- Jonathan S. Leff	Director	September 20, 2002
/s/ George McFadden ----- George McFadden	Director	September 20, 2002

II-4

EXHIBIT INDEX

NUMBER -----	EXHIBIT -----
5	Opinion and consent of Smith, Anderson, Blount, Dorsett, Mitchell & Jernigan, L.L.P.
23.1	Consent of PricewaterhouseCoopers LLP, Independent Accountants.
23.2	Consent of Smith, Anderson, Blount, Dorsett, Mitchell & Jernigan, L.L.P. is contained in Exhibit 5.
24	Power of Attorney. Reference is made to pages II-3 and II-4 of this Registration Statement.